FDA fast-tracks drug for cannabis withdrawal syndrome
PleoPharma has secured US Food and Drug Administration (FDA) Fast Track designation for PP-01, its lead asset for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder. “We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA… Read More